CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 127 target
Drug / intervention
Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)drug
Likely dose
Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04718584
NCT04718584Phase 2Unknown
CompareCT.gov

A Single-arm, Open, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) in the Treatment of Urinary and Male Genital Tumors

Dragonboat Biopharmaceutical Company Limited·interventional·Posted Jan 22, 2021·Updated Jan 22, 2021

In Brief

A Phase 2 clinical trial evaluating Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) for Bladder Cancer and 2 related conditions. Targeting 127 participants across 1 site.

Detailed Summary

This is a single-arm,open, multicenter, phase II clinical study of the efficacy and safety of human anti-PD-L1 monoclonal antibody Injection (LDP) in the treatment of urinary and male genital tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Renal Carcinoma, Advanced Penile Carcinoma
CountriesChina
CollaboratorsFudan University

Timeline

Phase 2UnknownOverdue
202120222023202420252026
First PostedJan 22, 2021
Enrollment StartSep 11, 2020
Primary CompletionNov 1, 2022
Study CompletionNov 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2.1 yearsPosted 5.4 years ago

Interventions

Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)drug

All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.